ProfileGDS5678 / 1456729_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 56% 56% 54% 55% 57% 56% 55% 55% 55% 56% 55% 56% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5960959
GSM967853U87-EV human glioblastoma xenograft - Control 23.4009456
GSM967854U87-EV human glioblastoma xenograft - Control 33.4016756
GSM967855U87-EV human glioblastoma xenograft - Control 43.2962254
GSM967856U87-EV human glioblastoma xenograft - Control 53.3124455
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5453357
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4948256
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.381855
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3368855
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3617555
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3970356
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3368355
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.417156
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3975756